KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Raw Materials (2016 - 2017)

Amgen has reported Raw Materials over the past 5 years, most recently at $237.0 million for Q2 2017.

  • Quarterly results put Raw Materials at $237.0 million for Q2 2017, changed N/A from a year ago — trailing twelve months through Jun 2017 was $237.0 million (changed N/A YoY), and the annual figure for FY2016 was $225.0 million, up 11.94%.
  • Raw Materials for Q2 2017 was $237.0 million at Amgen, up from $216.0 million in the prior quarter.
  • Over the last five years, Raw Materials for AMGN hit a ceiling of $237.0 million in Q2 2017 and a floor of $198.0 million in Q4 2014.
  • Median Raw Materials over the past 5 years was $216.5 million (2013), compared with a mean of $214.4 million.
  • Biggest five-year swings in Raw Materials: dropped 8.76% in 2014 and later grew 11.94% in 2016.
  • Amgen's Raw Materials stood at $217.0 million in 2013, then decreased by 8.76% to $198.0 million in 2014, then rose by 1.52% to $201.0 million in 2015, then increased by 11.94% to $225.0 million in 2016, then grew by 5.33% to $237.0 million in 2017.
  • The last three reported values for Raw Materials were $237.0 million (Q2 2017), $216.0 million (Q1 2017), and $225.0 million (Q4 2016) per Business Quant data.